The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from federal drug shortage list

The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and its Type 2 diabetes medicine Mounjaro is officially over. The determination comes two months after the FDA first removed the ingredient in both medicines,